5th Orphan Drugs & Rare Diseases Event

Description:
The global orphan drug market totaled nearly $123 billion in 2014 and will continue to grow to reach nearly $191 billion by 2019.* With such growth and innovation witnessed in this field now is the best time to discuss and strategize the best route to market.
In the past year (2015) alone, the Food and Drug Administration have approved 21 new entities. The orphan drug market has seen a dramatic increase in pharmacologic cures for rare diseases, such as Gaucher’s disease (Cerezyme/Imiglucerase), atypical Hemolytic Uremic Syndrome (Soliris/Eculizumab) and Non-Hodgkin’s Lymphoma (Rituxan/Rituximab). Such entities have revolutionized medicine and paved the way for other drug candidates to enter this space.


SMi’s 5th annual Orphan Drugs event will bring together leading industry professionals to discuss the latest regulatory developments, explore how to reduce costs and learn from the latest innovations in the orphan drug landscape.